Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C infection defined as positive anti-HCV antibodies and serum HCV-RNA \>1000 IU/ml, naive to antiviral treatment~* age \>18 years~Exclusion Criteria:~* Antidepressive treatment within the last 3 years~* Psychiatric diseases including major depressive disorders in past medical history~* Active substance abuse during the last 12 months~* Pregnancy, lactation, wish to become pregnant~* Hepatitis B (HBV)/HIV-coinfection~* Decompensated liver disease, hepatocellular carcinoma, history of bleeding esophageal varices~* Neutropenia (\<1500/ul), thrombocytopenia (\<70/nl), anemia (\<12g/dl in females, \<13g/dl in males)~* History of autoimmune disease~* History of organ transplantation, concomitant liver disease, severe cardiopulmonary disease, hemolytic anemia, malignant disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
- Placebo (Type: PLACEBO_COMPARATOR): After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).